What's new in

Biotech

Pharmatech

🔥 Lilly's Triple-G Drug Just Hit 30.3% Weight Loss. Then the FDA Line Moved to 2027.

Lilly's triple-G shot retatrutide hit 30.3% weight loss in Phase 3 — surgery territory. Then the FDA filing slipped to Q1 2027 over manufacturing.

Biotech

🔥 Lilly's Triple-Threat Shot Just Melted 55 Pounds — and Notched Its Fifth Phase 3 Win

Eli Lilly's triple-agonist shot retatrutide hit 22.6% weight loss in two more Phase 3 trials — its fifth straight win, with an FDA filing due Q1 2027.

Biotech

🔥 Merck Just Turned a $600-a-Month Injection Into a $315 Pill — and Cut Cholesterol 59%

Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a once-daily pill that cuts LDL up to 59%, matching the injectables at $315 a month.

Biotech

🔥 A $425,000 Kidney Drug Just Cleared the FDA — and It Hits Two Targets No One Had Hit at Once

Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.

Overnight: Scientists Found a Way to Slash Bad Cholesterol by 47% Using DNA: No Statins Needed

Feature Image: https://images.unsplash.com/photo-1648792940059-3b782a7b8b20?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w3ODQzODd8MHwxfHNlYXJj...

news

Roche's AI Gambit: 3,500 NVIDIA GPUs to Revolutionize Drug Discovery

BREAKING NEWS — In a move that signals the pharmaceutical industry's full-scale embrace of artificial intelligence, Swiss healthcare giant Roche has ...

Biotech

Can We 3D-Print Organs Yet? A Real Look at Biotech Progress

Scientists can now print mini-tissues, partial organs, and vascular networks. But printing a fully functional, transplant-ready human organ? Still at least 20–30 years away.